Dr. Andrew Sandler brings over 25 years of industry and clinical practice experience. Prior to joining AIS, he was Chief Medical Officer at Kiadis Pharma prior to its acquisition by Sanofi, providing strategic oversight of the company’s clinical development, clinical operations, regulatory affairs, medical affairs, safety/pharmacovigilance, scientific communication, and life -cycle management. Before that, he served as Senior Vice President, Medical Affairs at Medivation (Pfizer) where he provided strategic leadership direction in building and maintaining a Medical Affairs team for the development of their investigational agents in late-stage development while leading the life cycle management of their marketed products. Prior to Medivation, Dr. Sandler held various roles including Chief Medical Officer, Executive Vice President, R&D, Seattle Site Head and Senior Vice President, Clinical and Medial Affairs at Dendreon. Earlier in his career, Dr. Sandler was Chief Medical Officer at Spectrum Pharmaceuticals, Vice President and Head of Global Medical Affairs for Oncology at Bayer Healthcare Pharmaceuticals, and held various positions at Berlex Oncology/Schering AG and Seattle Genetics, Inc.
Dr. Sandler holds a M.D. degree from Mount Sinai Medical Center and a B.S. degree in Neuroscience from the University of Rochester. Dr. Sandler completed his residency in Internal Medicine at Mount Sinai Medical Center. Dr. Sandler also holds a Certificate in Epidemiology and Biostatistics and was a Fellow in Hematology/Medical Oncology in the Division of Hematology/Oncology at the University of California, San Francisco.